- Home
- FNLC vs LXEO Comparison
FNLC vs LXEO Comparison
Compare FNLC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- LXEO
- Stock Information
- Founded
- FNLC 1864
- LXEO 2017
- Country
- FNLC United States
- LXEO United States
- Employees
- FNLC N/A
- LXEO N/A
- Industry
- FNLC Major Banks
- LXEO
- Sector
- FNLC Finance
- LXEO
- Exchange
- FNLC Nasdaq
- LXEO Nasdaq
- Market Cap
- FNLC 323.2M
- LXEO 314.1M
- IPO Year
- FNLC 1999
- LXEO 2023
- Fundamental
- Price
- FNLC $28.60
- LXEO $6.20
- Analyst Decision
- FNLC
- LXEO Strong Buy
- Analyst Count
- FNLC 0
- LXEO 7
- Target Price
- FNLC N/A
- LXEO $22.71
- AVG Volume (30 Days)
- FNLC 17.9K
- LXEO 613.9K
- Earning Date
- FNLC 10-23-2024
- LXEO 11-13-2024
- Dividend Yield
- FNLC 5.06%
- LXEO N/A
- EPS Growth
- FNLC N/A
- LXEO N/A
- EPS
- FNLC 2.38
- LXEO N/A
- Revenue
- FNLC $78,192,000.00
- LXEO N/A
- Revenue This Year
- FNLC N/A
- LXEO N/A
- Revenue Next Year
- FNLC N/A
- LXEO N/A
- P/E Ratio
- FNLC $11.79
- LXEO N/A
- Revenue Growth
- FNLC N/A
- LXEO N/A
- 52 Week Low
- FNLC $21.77
- LXEO $5.77
- 52 Week High
- FNLC $31.05
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- FNLC 55.26
- LXEO 30.30
- Support Level
- FNLC $27.68
- LXEO $5.77
- Resistance Level
- FNLC $29.39
- LXEO $11.72
- Average True Range (ATR)
- FNLC 0.89
- LXEO 0.86
- MACD
- FNLC -0.05
- LXEO -0.18
- Stochastic Oscillator
- FNLC 54.38
- LXEO 7.23
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.